[Application of PROTACs in Hematological Malignancies--Review].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
; 31(6): 1921-1924, 2023 Dec.
Article
em Zh
| MEDLINE
| ID: mdl-38071084
ABSTRACT
Proteolysis-targeting chimeras (PROTACs) are heterobifunctional small molecules by utilizing the ubiquitin proteasome system (UPS) to degrade proteins of interest. PROTACs have exhibited unprecedented efficacy and specificity in degrading various oncogenic proteins because of their unique mechanism of action, ability to target "undruggable" and mutant proteins. A series of PROTACs have been developed to degrade multiple key protein targets for the treatment of hematologic malignancy. Notably, PROTACs that target BCL-XL, IRAK4, STAT3 and BTK have entered clinical trials. The known PROTACs that have the potential to be used to treat various hematological malignancies are systematically summarized in this review.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Limite:
Humans
Idioma:
Zh
Ano de publicação:
2023
Tipo de documento:
Article